D
David B. Badesch
Researcher at University of Colorado Denver
Publications - 208
Citations - 37183
David B. Badesch is an academic researcher from University of Colorado Denver. The author has contributed to research in topics: Pulmonary hypertension & Sildenafil. The author has an hindex of 69, co-authored 197 publications receiving 34204 citations. Previous affiliations of David B. Badesch include University of Colorado Hospital & Anschutz Medical Campus.
Papers
More filters
Journal ArticleDOI
A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension
Robyn J. Barst,Lewis J. Rubin,Walker Long,Michael D. McGoon,Stuart Rich,David B. Badesch,Bertron M. Groves,Victor F. Tapson,Robert C. Bourge,Bruce H. Brundage,Spencer K. Koerner,David Langleben,Cesar A. Keller,Srinivas Murali,Barry F. Uretsky,Linda M. Clayton,Maria M. Jöbsis,Shelmer D. Blackburn,Denise Shortino,James W. Crow +19 more
TL;DR: As compared with conventional therapy, the continuous intravenous infusion of epoprostenol produced symptomatic and hemodynamic improvement, as well as improved survival in patients with severe primary pulmonary hypertension.
Journal ArticleDOI
Bosentan therapy for pulmonary arterial hypertension.
Lewis J. Rubin,David B. Badesch,Robyn J. Barst,Nazzareno Galiè,Carol M. Black,Anne Keogh,Tomás Pulido,Adaani E. Frost,Sébastien Roux,Isabelle Leconte,Michael J. Landzberg,Gérald Simonneau +11 more
TL;DR: The endothelin-receptor antagonist bosentan is beneficial in patients with pulmonary arterial hypertension and is well tolerated at a dose of 125 mg twice daily.
Journal ArticleDOI
Sildenafil citrate therapy for pulmonary arterial hypertension.
Nazzareno Galiè,Hossein Ardeschir Ghofrani,Adam Torbicki,Robyn J. Barst,Lewis J. Rubin,David B. Badesch,Thomas R. Fleming,Tamiza Parpia,Gary Burgess,Angelo Branzi,Friedrich Grimminger,Marcin Kurzyna,Gérald Simonneau +12 more
TL;DR: Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m, and the incidence of clinical worsening did not differ significantly between the patients treated with s Bildenafils and those treated with placebo.
Journal ArticleDOI
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration With the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association
Vallerie V. McLaughlin,Stephen L. Archer,David B. Badesch,Robyn J. Barst,Harrison W. Farber,Jonathan R. Lindner,Michael A. Mathier,Michael D. McGoon,Myung H. Park,Robert S. Rosenson,Lewis J. Rubin,Victor F. Tapson,John Varga +12 more
TL;DR: In this paper, the authors discuss the role of the chairperson of FAHA and the chair's role in the FAHA Board of Trustee selection process and propose a new chairperson for FAHA.
Journal ArticleDOI
Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.
Richard N. Channick,Gérald Simonneau,Olivier Sitbon,Ivan M. Robbins,Adaani E. Frost,Victor F. Tapson,David B. Badesch,Sébastien Roux,Maurizio Rainisio,Frédéric Bodin,Lewis J. Rubin +10 more
TL;DR: Bosentan increases exercise capacity and improves haemodynamics in patients with pulmonary hypertension, suggesting that endothelin has an important role in pulmonary hypertension.